The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | ALPINE: QoL in patients with R/R CLL treated with zanubrutinib vs ibrutinib
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Apellis Pharmaceuticals, Leeds, UK, compares the health-related quality of life (QoL) outcomes associated with zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) from the ALPINE trial (NCT03734016). The ALPINE trial showed that zanubrutinib was more tolerable than ibrutinib and led to better overall outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
